{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T03:59:33Z","timestamp":1772855973344,"version":"3.50.1"},"reference-count":44,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2015,12,7]],"date-time":"2015-12-07T00:00:00Z","timestamp":1449446400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,5,1]]},"abstract":"<jats:p>Objective The objective of openFDA is to facilitate access and use of big important Food and Drug Administration public datasets by developers, researchers, and the public through harmonization of data across disparate FDA datasets provided via application programming interfaces (APIs).<\/jats:p>\n               <jats:p>Materials and Methods Using cutting-edge technologies deployed on FDA\u2019s new public cloud computing infrastructure, openFDA provides open data for easier, faster (over 300 requests per second per process), and better access to FDA datasets; open source code and documentation shared on GitHub for open community contributions of examples, apps and ideas; and infrastructure that can be adopted for other public health big data challenges.<\/jats:p>\n               <jats:p>Results Since its launch on June 2, 2014, openFDA has developed four APIs for drug and device adverse events, recall information for all FDA-regulated products, and drug labeling. There have been more than 20 million API calls (more than half from outside the United States), 6000 registered users, 20,000 connected Internet Protocol addresses, and dozens of new software (mobile or web) apps developed. A case study demonstrates a use of openFDA data to understand an apparent association of a drug with an adverse event.<\/jats:p>\n               <jats:p>Conclusion With easier and faster access to these datasets, consumers worldwide can learn more about FDA-regulated products.<\/jats:p>","DOI":"10.1093\/jamia\/ocv153","type":"journal-article","created":{"date-parts":[[2015,12,9]],"date-time":"2015-12-09T01:08:48Z","timestamp":1449623328000},"page":"596-600","source":"Crossref","is-referenced-by-count":88,"title":["OpenFDA: an innovative platform providing access to a wealth of FDA\u2019s publicly available data"],"prefix":"10.1093","volume":"23","author":[{"given":"Taha A","family":"Kass-Hout","sequence":"first","affiliation":[{"name":"U.S. Food and Drug Administration, Silver Spring, MD, USA"}]},{"given":"Zhiheng","family":"Xu","sequence":"additional","affiliation":[{"name":"U.S. Food and Drug Administration, Silver Spring, MD, USA"}]},{"given":"Matthew","family":"Mohebbi","sequence":"additional","affiliation":[{"name":"Iodine, Inc. 34 Clyde Street, San Francisco, CA 94107, USA"}]},{"given":"Hans","family":"Nelsen","sequence":"additional","affiliation":[{"name":"Iodine, Inc. 34 Clyde Street, San Francisco, CA 94107, USA"}]},{"given":"Adam","family":"Baker","sequence":"additional","affiliation":[{"name":"Iodine, Inc. 34 Clyde Street, San Francisco, CA 94107, USA"}]},{"given":"Jonathan","family":"Levine","sequence":"additional","affiliation":[{"name":"U.S. Food and Drug Administration, Silver Spring, MD, USA"}]},{"given":"Elaine","family":"Johanson","sequence":"additional","affiliation":[{"name":"U.S. Food and Drug Administration, Silver Spring, MD, USA"}]},{"given":"Roselie A","family":"Bright","sequence":"additional","affiliation":[{"name":"U.S. Food and Drug Administration, Silver Spring, MD, USA"}]}],"member":"286","published-online":{"date-parts":[[2015,12,7]]},"reference":[{"key":"2020110613022437200_ocv153-B1"},{"key":"2020110613022437200_ocv153-B2"},{"key":"2020110613022437200_ocv153-B3"},{"key":"2020110613022437200_ocv153-B4","article-title":"OpenFDA: Innovative Initiative Opens Door to Wealth of FDA\u2019s Publicly Available Data","author":"Kass-Hout","journal-title":"Food and Drug Administration"},{"key":"2020110613022437200_ocv153-B5"},{"key":"2020110613022437200_ocv153-B6"},{"key":"2020110613022437200_ocv153-B7"},{"key":"2020110613022437200_ocv153-B8","article-title":"Providing easy public access to prescription drug, over-the-counter drug, and biological product labeling","author":"Kass-Hout","journal-title":"Food and Drug Administration"},{"key":"2020110613022437200_ocv153-B9"},{"key":"2020110613022437200_ocv153-B10"},{"key":"2020110613022437200_ocv153-B11"},{"key":"2020110613022437200_ocv153-B12","article-title":"OpenFDA provides ready access to recall data","author":"Kass-Hout","journal-title":"Food and Drug Administration"},{"key":"2020110613022437200_ocv153-B13"},{"key":"2020110613022437200_ocv153-B14"},{"key":"2020110613022437200_ocv153-B15"},{"key":"2020110613022437200_ocv153-B16"},{"key":"2020110613022437200_ocv153-B17"},{"key":"2020110613022437200_ocv153-B18"},{"key":"2020110613022437200_ocv153-B19"},{"key":"2020110613022437200_ocv153-B20"},{"key":"2020110613022437200_ocv153-B21"},{"key":"2020110613022437200_ocv153-B22"},{"key":"2020110613022437200_ocv153-B23"},{"key":"2020110613022437200_ocv153-B24"},{"key":"2020110613022437200_ocv153-B25"},{"key":"2020110613022437200_ocv153-B26"},{"key":"2020110613022437200_ocv153-B27"},{"key":"2020110613022437200_ocv153-B28","article-title":"openFDA drug adverse events dataviz","author":"Ramstein","journal-title":"YouTube"},{"key":"2020110613022437200_ocv153-B29","article-title":"openFDA RR","author":"Levine"},{"key":"2020110613022437200_ocv153-B30","article-title":"openFDA RR-Event","author":"Levine"},{"key":"2020110613022437200_ocv153-B31","article-title":"openFDA Dynamic PRR","author":"Levine"},{"key":"2020110613022437200_ocv153-B32","article-title":"openFDA Change Point Analysis","author":"Levine"},{"key":"2020110613022437200_ocv153-B33","article-title":"Report Browser","author":"Levine"},{"key":"2020110613022437200_ocv153-B34"},{"key":"2020110613022437200_ocv153-B35","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1080\/10543409508835100","article-title":"Comparing reporting rates of adverse events between drugs with adjustment for year of marketing and secular trends in total reporting","volume":"5","author":"Tsong","year":"1995","journal-title":"J Biopharm Stat."},{"issue":"3","key":"2020110613022437200_ocv153-B36","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/pds.1535","article-title":"Estimating the extent of reporting to FDA: a case study of statin-associated rhabdomyolysis","volume":"17","author":"McAdams","year":"2008","journal-title":"Pharmacoepidemiol Drug Safety."},{"issue":"11","key":"2020110613022437200_ocv153-B37","doi-asserted-by":"crossref","first-page":"e7758","DOI":"10.1371\/journal.pone.0007758","article-title":"Breaking the news or fueling the epidemic? Temporal association between news media report volume and opioid-related mortality","volume":"4","author":"Dasgupta","year":"2009","journal-title":"PLoS One."},{"issue":"6","key":"2020110613022437200_ocv153-B38","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/pds.1742","article-title":"Quantitative signal detection using spontaneous ADR reporting","volume":"18","author":"Bate","year":"2009","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"9","key":"2020110613022437200_ocv153-B39","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1592\/phco.24.13.1099.38090","article-title":"Pharmacovigilance in the 21st century: new systematic tools for an old problem","volume":"24","author":"Szarfman","year":"2004","journal-title":"Pharmacotherapy"},{"key":"2020110613022437200_ocv153-B40","first-page":"205","article-title":"Current guidelines for high-density lipoprotein cholesterol in therapy and future directions","volume":"10","author":"Subedi","year":"2014","journal-title":"Vasc Health Risk Manag"},{"key":"2020110613022437200_ocv153-B41"},{"issue":"25 Suppl 2","key":"2020110613022437200_ocv153-B42","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1161\/01.cir.0000437738.63853.7a","article-title":"ACC\/AHA Guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults","volume":"129","author":"Stone","year":"2013","journal-title":"Circulation"},{"key":"2020110613022437200_ocv153-B43"},{"issue":"2","key":"2020110613022437200_ocv153-B44","doi-asserted-by":"crossref","first-page":"78","DOI":"10.5414\/CPP45078","article-title":"Aspirin reduces cutaneous flushing after administration of an optimized extended-release niacin formulation","volume":"45","author":"Cefali","year":"2007","journal-title":"Int J Clin Pharmacol Ther."}],"container-title":["Journal of the American Medical Informatics Association"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jamia\/article-pdf\/23\/3\/596\/34147863\/ocv153.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jamia\/article-pdf\/23\/3\/596\/34147863\/ocv153.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,6]],"date-time":"2020-11-06T18:54:18Z","timestamp":1604688858000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jamia\/article\/23\/3\/596\/2908999"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,7]]},"references-count":44,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2015,12,7]]},"published-print":{"date-parts":[[2016,5,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jamia\/ocv153","relation":{},"ISSN":["1067-5027","1527-974X"],"issn-type":[{"value":"1067-5027","type":"print"},{"value":"1527-974X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,7]]}}}